CG
ABBV icon

Cynosure Group’s AbbVie ABBV Stock Holding History

Cynosure Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,953
Closed -$446K – 200
2025
Q4 		$446K Sell
1,953
-254
-12% -$57.9K 0.05% 273
2025
Q3 		$511K Sell
2,207
-30
-1% -$6.11K 0.06% 176
2025
Q2 		$415K Buy
2,237
+569
+34% +$106K 0.05% 258
2025
Q1 		$349K Sell
1,668
-107
-6% -$20.8K 0.05% 230
2024
Q4 		$315K Sell
1,775
-855
-33% -$157K 0.05% 191
2024
Q3 		$519K Buy
2,630
+394
+18% +$73.5K 0.08% 149
2024
Q2 		$384K Buy
2,236
+357
+19% +$59.1K 0.06% 235
2024
Q1 		$342K Buy
+1,879
New +$324K 0.06% 179
2023
Q3 		– Sell
-5,307
Closed -$715K – 139
2023
Q2 		$715K Buy
+5,307
New +$778K 0.22% 93

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cynosure Group's ABBV Position: Q1 2026 in Review

Cynosure Group sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,953 shares — an estimated $446K sold.

Cynosure Group first reported a position in ABBV in Q2 2023 and held it in 9 quarters. The position peaked at $715K in Q2 2023. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cynosure Group reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Cynosure Group sold 1,953 AbbVie shares in Q1 2026, an estimated $446K.
  • Cynosure Group first reported a position in AbbVie in Q2 2023 and held it in 9 quarters.
  • Cynosure Group's AbbVie position peaked at $715K in Q2 2023.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.